Skip to main content

Supported by an educational grant from Neurocrine Biosciences, Inc.

Education

Moving Mountains with Molecules in Tardive Dyskinesia Module 3

All Education

Moving Mountains with Molecules in Tardive Dyskinesia Module 1

Moving Mountains with Molecules in Tardive Dyskinesia Module 2

Moving Mountains with Molecules in Tardive Dyskinesia Module 4

This accredited activity will help clinicians understand the prevalence of TD, recognize the risk factors, and introduce effective screening tools.

This accredited activity explores when to treat TD, and reviews some strategies that are not effective for managing TD and should be avoided.

These accredited videos discuss the role of VMAT2 inhibitors as the preferred treatment for tardive dyskinesia (TD), highlighting their mechanisms of action and differences in metabolism, as well a

View these accredited, narrated videos on deutetrabenazine and valbenazine, providing an overview of their dose-response relationships, highlighting their efficacy in managing tardive dyskinesia, a